The project, entitled “Prolonged Retention of Oral Peptide Formulations in the Gut”, will be hosted at BioMed X in Heidelberg. It aims to develop novel oral formulation technologies that achieve site-specific, prolonged retention of tablets or capsules within the lower small intestine. The key objective is to significantly improve the absorption and bioavailability of peptide-based therapeutics.

A research team will be formed to work on this challenge with support from BioMed X and Novo Nordisk, the company states. The research team will join the research community at BioMed X in Heidelberg, Germany.

“Novo Nordisk has been at the forefront of innovation in oral formulation of peptides and launched the first and only oral biologic on the market,” says Stephen Buckley, Scientific Vice President at Novo Nordisk. “We continuously look to push the boundaries of science through both internal and external innovation, and we are excited about the opportunities that this project may bring.”